-
1
-
-
84943138698
-
Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy
-
Lip GY, Skjoth F, Nielsen PB, Larsen TB. Non-valvular atrial fibrillation patients with none or one additional risk factor of the CHA2DS2-VASc score. A comprehensive net clinical benefit analysis for warfarin, aspirin, or no therapy. Thromb Haemost 2015; 114: 826–34.
-
(2015)
Thromb Haemost
, vol.114
, pp. 826-834
-
-
Lip, G.Y.1
Skjoth, F.2
Nielsen, P.B.3
Larsen, T.B.4
-
2
-
-
84895560449
-
Systematic review of observational studies assessing bleeding risk in patients with atrial fibrillation not using anticoagulants
-
Lopes LC, Spencer FA, Neumann I, Ventresca M, Ebrahim S, Zhou Q, Bhatnagar N, Schulman S, Eikelboom J, Guyatt G. Systematic review of observational studies assessing bleeding risk in patients with atrial fibrillation not using anticoagulants. PLoS ONE 2014; 9: e88131.
-
(2014)
PLoS ONE
, vol.9
-
-
Lopes, L.C.1
Spencer, F.A.2
Neumann, I.3
Ventresca, M.4
Ebrahim, S.5
Zhou, Q.6
Bhatnagar, N.7
Schulman, S.8
Eikelboom, J.9
Guyatt, G.10
-
3
-
-
84893179904
-
Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate
-
Majeed A, Meijer K, Larrazabal R, Arnberg F, Luijckx GJ, Roberts RS, Schulman S. Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate. Thromb Haemost 2014; 111: 233–9.
-
(2014)
Thromb Haemost
, vol.111
, pp. 233-239
-
-
Majeed, A.1
Meijer, K.2
Larrazabal, R.3
Arnberg, F.4
Luijckx, G.J.5
Roberts, R.S.6
Schulman, S.7
-
4
-
-
34547693119
-
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial
-
Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, Murray E; BAFTA Investigators; Midland Research Practices Network. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493–503.
-
(2007)
Lancet
, vol.370
, pp. 493-503
-
-
Mant, J.1
Hobbs, F.D.2
Fletcher, K.3
Roalfe, A.4
Fitzmaurice, D.5
Lip, G.Y.6
Murray, E.7
-
5
-
-
84908543945
-
Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials
-
Vanassche T, Hirsh J, Eikelboom JW, Ginsberg JS. Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials. Thromb Haemost 2014; 112: 918–23.
-
(2014)
Thromb Haemost
, vol.112
, pp. 918-923
-
-
Vanassche, T.1
Hirsh, J.2
Eikelboom, J.W.3
Ginsberg, J.S.4
-
6
-
-
77955872745
-
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey
-
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093–100.
-
(2010)
Chest
, vol.138
, pp. 1093-1100
-
-
Pisters, R.1
Lane, D.A.2
Nieuwlaat, R.3
de Vos, C.B.4
Crijns, H.J.5
Lip, G.Y.6
-
7
-
-
84889818750
-
The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation
-
Roldan V, Marin F, Manzano-Fernandez S, Gallego P, Vilchez JA, Valdes M, Vicente V, Lip GY. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol 2013; 62: 2199–204.
-
(2013)
J Am Coll Cardiol
, vol.62
, pp. 2199-2204
-
-
Roldan, V.1
Marin, F.2
Manzano-Fernandez, S.3
Gallego, P.4
Vilchez, J.A.5
Valdes, M.6
Vicente, V.7
Lip, G.Y.8
-
8
-
-
84951170841
-
Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores: clinical application requires focus on the reversible bleeding risk factors
-
Lip GY, Lane DA. Assessing bleeding risk in atrial fibrillation with the HAS-BLED and ORBIT scores: clinical application requires focus on the reversible bleeding risk factors. Eur Heart J 2015; 36: 3265–7.
-
(2015)
Eur Heart J
, vol.36
, pp. 3265-3267
-
-
Lip, G.Y.1
Lane, D.A.2
-
9
-
-
80052094564
-
A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study
-
Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol 2011; 58: 395–401.
-
(2011)
J Am Coll Cardiol
, vol.58
, pp. 395-401
-
-
Fang, M.C.1
Go, A.S.2
Chang, Y.3
Borowsky, L.H.4
Pomernacki, N.K.5
Udaltsova, N.6
Singer, D.E.7
-
10
-
-
84983735470
-
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation
-
O'Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, Kowey PR, Mahaffey KW, Chang P, Fonarow GC, Pencina MJ, Piccini JP, Peterson ED. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J 2015; 36: 3258–64.
-
(2015)
Eur Heart J
, vol.36
, pp. 3258-3264
-
-
O'Brien, E.C.1
Simon, D.N.2
Thomas, L.E.3
Hylek, E.M.4
Gersh, B.J.5
Ansell, J.E.6
Kowey, P.R.7
Mahaffey, K.W.8
Chang, P.9
Fonarow, G.C.10
Pencina, M.J.11
Piccini, J.P.12
Peterson, E.D.13
-
11
-
-
84975896253
-
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
-
Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, Wallentin L. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 2016; 387: 2302–11.
-
(2016)
Lancet
, vol.387
, pp. 2302-2311
-
-
Hijazi, Z.1
Oldgren, J.2
Lindback, J.3
Alexander, J.H.4
Connolly, S.J.5
Eikelboom, J.W.6
Ezekowitz, M.D.7
Held, C.8
Hylek, E.M.9
Lopes, R.D.10
Siegbahn, A.11
Yusuf, S.12
Granger, C.B.13
Wallentin, L.14
-
12
-
-
84988452162
-
Low performance of bleeding risk models in the very elderly with atrial fibrillation using vitamin K antagonists
-
Focks JJ, van Vugt SPG, Albers-Akkers MT, Lamfers EJ, Bloem-de-Vries LM, Verheugt FW, Brouwer M. Low performance of bleeding risk models in the very elderly with atrial fibrillation using vitamin K antagonists. J Thromb Haemost 2016; 14: 1715–24.
-
(2016)
J Thromb Haemost
, vol.14
, pp. 1715-1724
-
-
Focks, J.J.1
van Vugt, S.P.G.2
Albers-Akkers, M.T.3
Lamfers, E.J.4
Bloem-de-Vries, L.M.5
Verheugt, F.W.6
Brouwer, M.7
-
13
-
-
82655172003
-
Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association (EHRA), endorsed by the European Society of Cardiology (ESC) Working Group on Thrombosis
-
Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Marin F, Palareti G, Kirchhof P. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association (EHRA), endorsed by the European Society of Cardiology (ESC) Working Group on Thrombosis. Thromb Haemost 2011; 106: 997–1011.
-
(2011)
Thromb Haemost
, vol.106
, pp. 997-1011
-
-
Lip, G.Y.1
Andreotti, F.2
Fauchier, L.3
Huber, K.4
Hylek, E.5
Knight, E.6
Lane, D.7
Levi, M.8
Marin, F.9
Palareti, G.10
Kirchhof, P.11
-
14
-
-
33748360506
-
Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation
-
Lip GY, Lane D, van Walraven C, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke 2006; 37: 2294–300.
-
(2006)
Stroke
, vol.37
, pp. 2294-2300
-
-
Lip, G.Y.1
Lane, D.2
van Walraven, C.3
Hart, R.G.4
-
15
-
-
84878337221
-
Biomarkers in atrial fibrillation: a clinical review
-
Hijazi Z, Oldgren J, Siegbahn A, Granger CB, Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J 2013; 34: 1475–80.
-
(2013)
Eur Heart J
, vol.34
, pp. 1475-1480
-
-
Hijazi, Z.1
Oldgren, J.2
Siegbahn, A.3
Granger, C.B.4
Wallentin, L.5
-
16
-
-
84963800755
-
Major bleeding in patients with non-valvular atrial fibrillation: impact of time in therapeutic range on contemporary bleeding risk scores
-
Proietti M, Senoo K, Lane DA, Lip GY. Major bleeding in patients with non-valvular atrial fibrillation: impact of time in therapeutic range on contemporary bleeding risk scores. Sci Rep 2016; 6: 24376.
-
(2016)
Sci Rep
, vol.6
, pp. 24376
-
-
Proietti, M.1
Senoo, K.2
Lane, D.A.3
Lip, G.Y.4
-
17
-
-
84960194211
-
Evaluation of the HAS-BLED, ATRIA and ORBIT bleeding risk scores in atrial fibrillation patients on warfarin
-
Senoo K, Proietti M, Lane DA, Lip GY. Evaluation of the HAS-BLED, ATRIA and ORBIT bleeding risk scores in atrial fibrillation patients on warfarin. Am J Med 2016; 129: 600–7.
-
(2016)
Am J Med
, vol.129
, pp. 600-607
-
-
Senoo, K.1
Proietti, M.2
Lane, D.A.3
Lip, G.Y.4
-
18
-
-
84861231518
-
Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study
-
Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012; 125: 2298–307.
-
(2012)
Circulation
, vol.125
, pp. 2298-2307
-
-
Friberg, L.1
Rosenqvist, M.2
Lip, G.Y.3
-
19
-
-
84897045662
-
Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation
-
Lahaye S, Regpala S, Lacombe S, Sharma M, Gibbens S, Ball D, Francis K. Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost 2014; 111: 465–73.
-
(2014)
Thromb Haemost
, vol.111
, pp. 465-473
-
-
Lahaye, S.1
Regpala, S.2
Lacombe, S.3
Sharma, M.4
Gibbens, S.5
Ball, D.6
Francis, K.7
-
20
-
-
84897075930
-
Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation
-
Lane DA, Lip GY. Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation. Thromb Haemost 2014; 111: 381–3.
-
(2014)
Thromb Haemost
, vol.111
, pp. 381-383
-
-
Lane, D.A.1
Lip, G.Y.2
|